Crispr Therapeutics (CRSP) Rating Increased to Hold at ValuEngine
ValuEngine upgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a sell rating to a hold rating in a research report sent to investors on Wednesday.
Other analysts have also recently issued reports about the company. SunTrust Banks raised Crispr Therapeutics from a hold rating to a buy rating in a research note on Tuesday, January 23rd. Piper Jaffray Companies reissued a buy rating and set a $22.75 target price (down from $39.00) on shares of Crispr Therapeutics in a research note on Wednesday, January 10th. BidaskClub raised Crispr Therapeutics from a hold rating to a buy rating in a research note on Thursday, January 4th. Oppenheimer reaffirmed a hold rating on shares of Crispr Therapeutics in a research note on Thursday, December 21st. Finally, Cann reaffirmed a hold rating on shares of Crispr Therapeutics in a research note on Sunday, December 10th. One analyst has rated the stock with a sell rating, four have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Crispr Therapeutics has a consensus rating of Buy and an average target price of $28.45.
Shares of Crispr Therapeutics (NASDAQ:CRSP) opened at $50.02 on Wednesday. Crispr Therapeutics has a 52 week low of $13.50 and a 52 week high of $51.00. The stock has a market capitalization of $2,295.47, a P/E ratio of -37.89 and a beta of 3.63.
Institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN grew its stake in shares of Crispr Therapeutics by 459.7% during the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after acquiring an additional 6,560 shares in the last quarter. Capital Investment Advisory Services LLC bought a new position in shares of Crispr Therapeutics during the 3rd quarter worth approximately $193,000. Ark Investment Management LLC bought a new position in shares of Crispr Therapeutics in the second quarter valued at $206,000. Creative Planning bought a new position in shares of Crispr Therapeutics in the fourth quarter valued at $243,000. Finally, Vanguard Group Inc. bought a new position in shares of Crispr Therapeutics in the second quarter valued at $273,000. 24.55% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Crispr Therapeutics (CRSP) Rating Increased to Hold at ValuEngine” was first posted by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.dailypolitical.com/2018/03/04/crispr-therapeutics-crsp-rating-increased-to-hold-at-valuengine.html.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.